Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Flagship Pioneering is seeking an experienced Finance leader to join as Director/Senior Director of FP&A. You will partner with portfolio companies, provide business insights, and lead budgeting, forecasting, and long-range planning.
This role shapes company performance and financial reporting for a fast-growing biotechnology startup ecosystem. You will collaborate with scientists and management, drive cross-functional initiatives, and support financing rounds.
What if…you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies in order to transform healthcare and sustainability?
Flagship’s venture creation engine, where companies such as Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), and Editas Medicines (NASDAQ: EDIT) were conceived and created. Since Flagship’s founding in 2000, the firm has originated and fostered the development of more than 100 scientific ventures, resulting in over $34 billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.
Flagship Pioneering is seeking an experienced and talented finance leader to join a first-in-category organization. TheDirector/Senior Director of FP&Awill be an instrumental player partnering with portfolio companies and will be responsible for providing business insights to our leaders to measure progress on company performance and assist with enhancing companywide financial planning and reporting including building of annual budget and managing the Long-Range-Plan Process.
We are creative optimists and we would love for you to consider joining our team! See all our open opportunities across Flagship Pioneering’s Ecosystem!
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $34 billion in aggregate value. To date, Flagship is backed by more than $4.4 billion of aggregate capital commitments, of which over $1.9 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including: Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics, Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
We believe pioneering is best done by teams, and that it is a process that can be taught, learned, and replicated. Learn more about our Company Creation Model.
Can Breakthrough Innovations Be Made Systematically? A Conversation With Noubar Afeyan, Flagship Pioneering’s CEO.
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.